Can shoveling snow put your heart at risk?

Follow me on Twitter @RobShmerling When it comes to heart disease, there’s lots of advice. There are heart-healthy diets and exercise programs to follow. Of course, if you smoke, you’re urged to stop. For those at highest risk or who already have heart disease, there are medications to take and monitoring of your condition to keep track of. A recent study suggests that for people who are at high risk for heart disease or who already have it, there’s a bit of new advice: don’t shovel snow. Shoveling snow and heart attack According to past estimates, about 100 people — mostly men — die during or just after shoveling snow each year in the US. Many more are admitted to the hospital with chest pain or other heart problems. This latest research further explored the details of this connection. Researchers correlated admissions to the hospital and deaths due to heart attack the day after it snowed in Canada during the years 1981 to 2014. This included more than 128,000 hospital admissions and more than 68,000 deaths due to heart attack. Here’s what they found: The deeper the snow, the more men were admitted for heart attacks. For example, for snowfalls of more than eight inches, there was a 16% increase in hospital admissions compared to days with no snow. The deeper the snow, the more men died of heart attacks.  A 34% increase was observed the day after an eight-inch snowfall, and higher rates were noted when even more snow fell. Simil...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Health Heart Health Source Type: blogs

Related Links:

RARITAN, NJ, May 13, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today results from the final analysis of the pivotal Phase 3 SPARTAN study demonstrating ERLEADA® (apalutamide) in combination with androgen deprivation therapy (ADT) significantly improved overall survival (OS), compared to ADT alone, in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who were at high risk of developing metastases.[i] Results will be presented at the American Society of Clinical Oncology (ASCO) Virtual Scientific Program (Abstract #5516) beginning May 29th. ERLEADA® i...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to ...
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
Working hard and feeling like you don’t have any time to exercise? Well, the reality is we all have time. If you’re feeling bad about not exercising enough or at all, some exciting data crunching from a recent British Journal of Sports Medicine (BJSM) analysis of research on running and mortality rates could supply the motivation you need. What amount of running is better than no running? An abundance of research supports the health benefits of exercise. In a blog post last year, I wrote about a study in JAMA that took the first look at the effect of various cardiorespiratory fitness levels on longevity. That s...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Exercise and Fitness Health Healthy Aging Heart Health Source Type: blogs
RARITAN, N.J., February 3, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today multiple data presentations from a robust solid tumor portfolio that will be featured at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place February 13-15 in San Francisco. Company-sponsored data presentations will include clinical results for ERLEADA® (apalutamide) and niraparib in prostate cancer; and BALVERSA™ (erdafitinib) in bladder cancer. “We are committed to improving outcomes in patients with prostate and bladder cancer where high unmet ...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
By ANISH KOKA, MD Mr. Smith has a problem.  He can’t see.  Even this cardiologist knows why.  The not so subtle evidence lies in the cloudy lens in front of his pupils.  He is afflicted with cataracts that obstruct his vision to the point he can’t really do his job refurbishing antique furniture safely.  His other problem is that he hates doctors. He hasn’t had reason to see one for more than a decade.  He’s 68, takes no medications, smokes a pack of cigarettes a day, and is a master of one word answers. He’s in my office because he needs a medical eval...
Source: The Health Care Blog - Category: Consumer Health News Authors: Tags: Medical Practice Patients Physicians Anish Koka cardiology low-value testing Source Type: blogs
Publication date: March 2020Source: American Heart Journal, Volume 221Author(s): Geoffrey Lau, Maria Koh, Peter A. Kavsak, Michael J. Schull, David W.J. Armstrong, Jacob A. Udell, Peter C. Austin, Xuesong Wang, Dennis T. KoBackgroundHigh-sensitivity cardiac troponin (hs-cTn) assays enhance detection of lower circulating troponin concentrations, but the impact on outcomes in clinical practice is unclear. Our objective was to compare outcomes of chest pain patients discharged from emergency departments (EDs) using hs-cTn and conventional troponin (cTn) assays.MethodsWe conducted an observational study of chest pain patients ...
Source: American Heart Journal - Category: Cardiology Source Type: research
Did you ever wonder why medical research seems to flip-flop so often? Eggs used to be terrible for your health; now they’re not so bad. Stomach ulcers were thought to be due to stress and a “type A personality” but that’s been disproven. I was taught that every postmenopausal woman should take hormone replacement therapy to prevent heart disease and bone loss; now it’s considered way too risky. It can make you question every bit of medical news you hear. But maybe that’s not such a bad thing. Questioning what you read or hear is reasonable. And maybe medical reversals — when new re...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Health Medical Research Prevention Tests and procedures Source Type: blogs
This study suggests that for most, managing CAD with medications alone (the conservative approach) is as safe and effective as the more invasive strategy of cardiac catheterization and opening of the blocked artery. Findings of the ISCHEMIA trial ISCHEMIA followed over 5,000 patients with significant narrowing in one or more coronary arteries. Half of the patients were randomly selected to receive conservative treatment with optimal medical therapy (OMT) and lifestyle changes to treat risk factors such as high blood pressure and high cholesterol. The other half were given OMT and also sent for cardiac catheterization (thre...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Health Source Type: blogs
Rationale: Coronary angiography (CAG) findings of acute myocardial infarction (AMI) in pregnant women are characterized by a high incidence of normal coronary arteries. This is the first report of AMI with normal coronary arteries during pregnancy, showing coronary spasm and pregnancy-related acquired protein S (PS) deficiency. Patient concerns: A 30-year-old Japanese woman was admitted to an emergency department. One hour before admission, she developed sudden onset of precordial discomfort, back pain, and dyspnea. She was a primigravida at 39 weeks’ gestation and had no abnormality in the pregnancy thus far. S...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research
A 50-something woman with history of CHF of unknown etiology, and of HTN, presented for evaluation of chest pressure.Her BP was 223/125, Sp02 98% on RA. HR 106, RR 18. Here was her ED ECG:There is sinus rhythm with Left Bundle Branch Block (LBBB)There is a large amount of ST Elevation in V2 and V3 (more than 5 mm)Thus, this meets the unweighted Sgarbossa Criteria of 5 mm of discordant ST ElevationBut it does NOT meet the Smith Modified Sgarbossa Criteria, which depend on the ST/S ratio.This ratio is critical because LBBB with very large depolarization voltage (QRS) also has very large repolarization voltage (ST/T).Her...
Source: Dr. Smith's ECG Blog - Category: Cardiology Authors: Source Type: blogs
More News: Blogging | Canada Health | Cardiology | Cardiovascular | Diets | Environmental Health | Harvard | Heart | Heart Attack | Heart Disease | Hospitals | Hypertension | Men | Nutrition | Pain | Smokers | Sports Medicine | Study | Women